We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Timber Pharmaceuticals Inc (TMBR) USD0.001

Sell:$0.0981 Buy:$0.11 Change: $0.0007 (0.68%)
Market closed |  Prices as at close on 8 August 2022 | Switch to live prices |
Sell:$0.0981
Buy:$0.11
Change: $0.0007 (0.68%)
Market closed |  Prices as at close on 8 August 2022 | Switch to live prices |
Sell:$0.0981
Buy:$0.11
Change: $0.0007 (0.68%)
Market closed |  Prices as at close on 8 August 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Timber Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of treatments for orphan dermatologic diseases. It is also focused on developing non-systemic treatments for rare dermatologic diseases, including congenital ichthyosis (CI), facial angiofibromas (FAs) in the tuberous sclerosis complex (TSC), and sclerotic skin diseases. Its lead mid to late-stage programs are TMB-001 and TMB-002. TMB-003 is its earliest stage program. TMB-001 is a topical formulation of isotretinoin using its IPEG delivery system, completed its Phase IIb clinical trials for the treatment of moderate to severe subtypes of CI. TMB-002 is a topical formulation of rapamycin, which is being evaluated in a Phase IIb clinical trial for the treatment of FAs in TSC. TMB-003 is a formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist for the treatment of sclerotic skin diseases.

Contact details

Address:
110 ALLEN ROAD, SUITE 401
BASKING RIDGE
07920
United States
Telephone:
+1 (914) 2053481
Website:
https://www.timberpharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
TMBR
ISIN:
US8870801094
Market cap:
$6.55 million
Shares in issue:
63.70 million
Sector:
Pharmaceuticals
Exchange:
New York Stock Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • John Koconis
    Chairman of the Board, President, Chief Executive Officer
  • Joseph Lucchese
    Chief Financial Officer, Executive Vice President, Treasurer, Secretary
  • Alan Mendelsohn
    Executive Vice President, Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.